Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Felix Sahm

Showing results (401-410 of 451) with videos related to

Pageof 46
Sort By:
Neuro-Oncology|April 18, 2025
Molecular signatures define BAP1-altered meningioma as a distinct CNS tumor with deregulation of Polycomb repressive complex target genesPhilipp Sievers, Sonali Arora, Thomas Hielscher, et al.
Acta Neuropathologica Communications|October 30, 2019
Tumors diagnosed as cerebellar glioblastoma comprise distinct molecular entitiesAnnekathrin Reinhardt, Damian Stichel, Daniel Schrimpf, et al.
Cell Stem Cell|February 12, 2025
Individualized patient tumor organoids faithfully preserve human brain tumor ecosystems and predict patient response to therapyTianping Peng, Xiujian Ma, Wei Hua, et al.
Neuro-Oncology|June 3, 2026
Primary Mismatch Repair Deficient Glioma (PMMRDG), IDH-wildtype and H3-wildtype: A Giant Cell Tumor with Potential for Long-Term Survival Occurring at all AgesAbigail K Suwala, Dennis Friedel, Felix E Hinz, et al.
Acta Neuropathologica|November 26, 2025
Loss of global DNA hypermethylation is prognostic in IDH-mutant and 1p/19q-codeleted oligodendrogliomasFelix E Hinz, Dennis Friedel, Franziska M Ippen, et al.
The Lancet. Oncology|September 4, 2025
The effect of TERT promoter mutation on predicting meningioma outcomes: a multi-institutional cohort analysisKarenna J Groff, Ruchit V Patel, Yang Feng, et al.
Neuro-Oncology|July 22, 2025
Distinct molecular profile and outcome of oligodendroglioma, IDH-mutant, 1p/19q-codeleted and TERTp-wildtype: a grade 1 oligodendroglioma of young patients?Filippo Nozzoli, Ramin Rahmanzade, Simone Schmid, et al.
Acta Neuropathologica Communications|April 5, 2024
CNS tumors with PLAGL1-fusion: beyond ZFTA and YAP1 in the genetic spectrum of supratentorial ependymomasArnault Tauziède-Espariat, Yvan Nicaise, Philipp Sievers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 25, 2020
Nonmetastatic Medulloblastoma of Early Childhood: Results From the Prospective Clinical Trial HIT-2000 and An Extended Validation CohortMartin Mynarek, Katja von Hoff, Torsten Pietsch, et al.
Cancer Discovery|March 20, 2021
ZFTA-RELA Dictates Oncogenic Transcriptional Programs to Drive Aggressive Supratentorial EpendymomaAmir Arabzade, Yanhua Zhao, Srinidhi Varadharajan, et al.
Pageof 46

Showing results (401-410 of 451) with videos related to

Sort By:
Pageof 46
Neuro-Oncology|April 18, 2025
Molecular signatures define BAP1-altered meningioma as a distinct CNS tumor with deregulation of Polycomb repressive complex target genesPhilipp Sievers, Sonali Arora, Thomas Hielscher, et al.
Acta Neuropathologica Communications|October 30, 2019
Tumors diagnosed as cerebellar glioblastoma comprise distinct molecular entitiesAnnekathrin Reinhardt, Damian Stichel, Daniel Schrimpf, et al.
Cell Stem Cell|February 12, 2025
Individualized patient tumor organoids faithfully preserve human brain tumor ecosystems and predict patient response to therapyTianping Peng, Xiujian Ma, Wei Hua, et al.
Neuro-Oncology|June 3, 2026
Primary Mismatch Repair Deficient Glioma (PMMRDG), IDH-wildtype and H3-wildtype: A Giant Cell Tumor with Potential for Long-Term Survival Occurring at all AgesAbigail K Suwala, Dennis Friedel, Felix E Hinz, et al.
Acta Neuropathologica|November 26, 2025
Loss of global DNA hypermethylation is prognostic in IDH-mutant and 1p/19q-codeleted oligodendrogliomasFelix E Hinz, Dennis Friedel, Franziska M Ippen, et al.
The Lancet. Oncology|September 4, 2025
The effect of TERT promoter mutation on predicting meningioma outcomes: a multi-institutional cohort analysisKarenna J Groff, Ruchit V Patel, Yang Feng, et al.
Neuro-Oncology|July 22, 2025
Distinct molecular profile and outcome of oligodendroglioma, IDH-mutant, 1p/19q-codeleted and TERTp-wildtype: a grade 1 oligodendroglioma of young patients?Filippo Nozzoli, Ramin Rahmanzade, Simone Schmid, et al.
Acta Neuropathologica Communications|April 5, 2024
CNS tumors with PLAGL1-fusion: beyond ZFTA and YAP1 in the genetic spectrum of supratentorial ependymomasArnault Tauziède-Espariat, Yvan Nicaise, Philipp Sievers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 25, 2020
Nonmetastatic Medulloblastoma of Early Childhood: Results From the Prospective Clinical Trial HIT-2000 and An Extended Validation CohortMartin Mynarek, Katja von Hoff, Torsten Pietsch, et al.
Cancer Discovery|March 20, 2021
ZFTA-RELA Dictates Oncogenic Transcriptional Programs to Drive Aggressive Supratentorial EpendymomaAmir Arabzade, Yanhua Zhao, Srinidhi Varadharajan, et al.
Pageof 46